ReviewWorld journal of nuclear medicine2026
Redefining Soft Tissue Sarcoma Imaging: The Expanding Role of Positron Emission Tomography/Computed Tomography: A Review.
Review in World journal of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Soft tissue sarcomas (STSs) are a heterogeneous group of mesenchymal malignancies with diverse biological behavior, posing significant challenges in tumor grading, prognostic stratification, and early treatment response assessment. While magnetic resonance imaging (MRI) remains the standard modality for local tumor evaluation, its ability to characterize tumor biology and predict clinical outcomes is limited. Advanced imaging, particularly positron emission tomography/computed tomography (PET/CT), plays a critical role in improving disease characterization and supporting personalized patient management. Methods: This narrative review summarizes the role of PET/CT in STS, focusing on established and emerging radiotracers, quantitative PET metrics, and multiparametric imaging approaches, along with their clinical applications. Results: Conclusion: PET/CT is a key modality in STS, enabling comprehensive assessment of tumor biology and supporting personalized management. Integration of quantitative metrics, novel radiotracers, and advanced analytical techniques is expected to improve diagnostic accuracy, prognostication, and treatment planning. Further large-scale studies are required to standardize methodologies and confirm clinical impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.